Ampicillin and Sulbactam for Injection- Newlystar (Ningbo) Medtech Co., Ltd.

Newlystar (Ningbo) Medtech Co., Ltd.

We only export finished medicines. We are a professional trading company, if you must make deal with manufacturer, please find manufacturer directly.
We export to Europe, to Latin American, to Asia, to Africa. We have clients in more than 30 countries.
Each year, we have big deal with a lot manufacturers in China, because the quantity is big, our price is competitive.
And to make our business longer and stable, we only deal with manufacturers with good quality.

We have a quality department dealing with registration dossier and help manufacturers pass higher GMP inspection. We are the best one in China in this issue.

Above are features of Newlystar.
If you want read more information about our company, please go ahead. But usually, offical company introduction, doesn't have many useful information.(That is my personal opinion.)

Newlystar Medtech cooperate with state of the art facilities in China and export medicines to 30+ countries worldwide. Include East Europe, Central and southeast Asia, Latin America, Africa etc. We also contract manufacture for European companies.

Newlystar-Medtech is a well established and professional supplier of Finished Pharmaceutical, Active Pharmaceutical Ingredient(API) and Medical Devices. With a proven track record of passed years, Newlystar-Medtech has been recognized by her customers as a high-quality and reliable supplier not only on products, but also on assistance for audit and improvement of GMP level, quality management system, EHS management system and registration dossier support, etc.
The essence of Newlystar-Medtech's activites, is a commitment to her customers with professional service and high-quality products with effective cost and innovative solutions. All pharmacists work in Newlystar-Medtech like a bridge link the customers and Chinese manufacturers, especially, their professional working is to make the formulation manufacturers who is familiar with Chinese Pharmacopoeia to understand well the international requirement, to ensure the success of customers.
The advantages on professional working and strongly representative base on first-class manufacturing partners in China, enable Newlystar-Medtech to provide her customers with a wide range and high-tech products, best services and capabilities for their actions in tender, distributing and improvement in their national healthcare system. Newlystar-Medtech also dedicates herself to sourcing quality medical products for Chinese market.

Services and capabilities include:
1. Sourcing quality manufacturer
2. Contract manufacturing;
3. Conduct audits to suppliers (pharmaceutical plants);
4. Consultation on audit and improvement of GMP level, quality management system and EHS management system;
5. Regulatory support, registration dossier working;

Newlystar Medtech, your professional one-stop China Souring Partner.

Home>Product>Ampicillin and Sulbactam for Injection

Ampicillin and Sulbactam for Injection

FOB Price:Get Latest Price >
Min.Order:50000 Vial(s)
Payment Terms:L/C , T/T

Favorite

Newlystar (Ningbo) Medtech Co., Ltd.

Business Type:Trader

Country/Region:China

Ddu Verified

HOT Rank

6/10

Product Information

Dosage Form:Powder
Route of Administration:Intravenous Drip
Shelf Life:3 years
Storage:Sealed

Description

Product : Ampicillin and Sulbactam for Injection

Specification : 1.5g, 3.0g

Standard : BP, USP

Description :

Vials of 1.5 g containing 1.0 g Ampicillin (as sodium salt) and 500 mg Sulbactam (as sodium salt);

Vials of 3.0 g containing 2 g Ampicillin (as sodium salt) and 1 g Sulbactam (as sodium salt).

Indication and usage :

Ampicillin and Sulbactam For Injection is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below.

Skin and Skin Structure Infections caused by beta-lactamase producing strains of Staphylococcus aureus, Escherichia coli,* Klebsiella spp.* (including K. pneumoniae*), Proteus mirabilis,* Bacteroides fragilis,* Enterobacter spp.,* and Acinetobacter calcoaceticus.*

NOTE: For information on use in pediatric patients see PRECAUTIONS–Pediatric Use and Clinical Studies sections.

Intra-Abdominal Infections caused by beta-lactamase producing strains of Escherichia coli, Klebsiella spp. (including K. pneumoniae*), Bacteroides spp. (including B. fragilis), and Enterobacter spp.*

Gynecological Infections caused by beta-lactamase producing strains of Escherichia coli,* and Bacteroides spp.* (including B. fragilis*).

While Ampicillin and Sulbactam For Injection is indicated only for the conditions listed above, infections caused by ampicillin-susceptible organisms are also amenable to treatment with Ampicillin and Sulbactam For Injection due to its ampicillin content. Therefore, mixed infections caused by ampicillin-susceptible organisms and beta-lactamase producing organisms susceptible to Ampicillin and Sulbactam For Injection should not require the addition of another antibiotic.

Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify the organisms causing infection and to determine their susceptibility to Ampicillin and Sulbactam For Injection.

Therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies when there is reason to believe the infection may involve any of the beta-lactamase producing organisms listed above in the indicated organ systems. Once the results are known, therapy should be adjusted if appropriate.

To reduce the development of drug-resistant bacteria and maintain effectiveness of Ampicillin and Sulbactam For Injection and other antibacterial drugs, Ampicillin and Sulbactam For Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

* Efficacy for this organism in this organ system was studied in fewer than 10 infections.